Drugs of interest to pathologists
Drugs related to surgical pathology
Vismodegib

Author: Him G. Kwee, M.D. (see Authors page)

Revised: 11 December 2017, last major update February 2012

Copyright: (c) 2002-2017, PathologyOutlines.com, Inc.

PubMed Search: Vismodegib [ti] "loattrfree full text"[sb]

Cite this page: Kwee, H.G. Vismodegib. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/drugseviredge.html. Accessed December 14th, 2017.
Definition / general
  • Artificial inhibitor of the hedgehog signaling pathway
Trade name
  • Eviredge®
Clinical information
  • Approved by U.S. Food and Drug Administration on January 30, 2012 for:
    • Metastatic basal cell carcinoma or locally advanced basal cell carcinoma in adults that has relapsed after surgery or that cannot be treated with surgery or radiation (Genentech: Highlights of Prescribing Information [Accessed 7 December 2017])
    • Abnormal hedgehog signaling is implicated in more than 90% of basal cell carcinoma cases
    • Vismodegib is an antagonist of the smoothened receptor (SMO) of the hedgehold signaling pathway
    • Cost estimate: $7,500 a month (San Francisco Chronicle, January 31, 2012)
    • Clinical trials are underway studying vismodegib in metatatic colon cancer, small cell lung carcinoma, metastatic stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma
Clinical side effects
  • Vismodegib is embryotoxic and teratogenic in animals; teratogenic effects included midline malformations, missing digits and other irreversible malformations
  • Drug should not be used during pregnancy
  • Female patients that could become pregnant should be advised of the need of contraception up to 7 months after the drug is discontinued
  • Male patients using the drug should be advised of the risk of exposure to their female partners through semen, even after vasectomy, up to 2 months after the drug is discontinued
  • Patients on this drug should not donate blood or blood products up to 7 months after the drug is discontinued
  • It is not known whether the drug is excreted in breast milk but it has the potential to cause serious side effects to the nursing infant
  • Side effects include muscle spasms, alopecia, anorexia, weight loss, diarrhea, constipation, dysgeusia / ageusia, fatigue, arthralgia, hyponatremia, hypokalemia or azotemia (Reuters: FDA approves Roche skin cancer drug [Accessed 7 December 2017])
Molecular theory
  • Hedgehog signaling pathway is one of the key regulators of animal and human development; it gives embryonic cells information that they need to make the embryo develop properly
  • Aberrations may cause spontaneous abortion or severe fetal malformations such as holoprosencephaly and cyclopia
  • Pathway is normally inactive in differentiated cells but is important to regulate adult stem cells involved in maintenance and regeneration of adult tissue
  • Hedgehog signaling pathway comprises three ligands, sonic (SHH), Indian (IHH) and desert (DHH) and two interacting transmembrane receptors, patched (PTC) and smoothened (SMO)
  • In the absence of ligand binding, PTC and SMO form a repressive complex that inhibits cell proliferation
  • Abnormal activation of the hedgehog pathway, such as via mutations, leads to development of disease through transformation of adult stem cells into cancer stem cells
  • Activation of the hedgehog pathway increases angiogenic factors (angiopoietin 1 and angiopoietin 2), cyclin D1, cyclin B1 and antiapoptotic genes and decreases apoptotic genes (FAS, Wikipedia: Hedgehog signaling pathway [Accessed 7 December 2014])
  • Activation of the hedgehog signaling pathway may be implicated in the development of basal cell carcinoma, prostate cancer, breast cancer, medulloblastoma, rhabdomyosarcoma, pancreatic cancer, stomach cancer, colon cancer, gliomas, leukemia, lymphoma, melanoma and probably other malignancies